Business Description
Prescient Therapeutics Ltd
ISIN : AU000000PTX3
Total Employee Number:
1Description
Prescient Therapeutics Ltd is conducting clinical studies and other research and development relating to the company's proprietary technologies and products, particularly PTX-100; Business development activities to support the promotion and partnering of Prescient's proprietary technologies and products. The company has single operating segment, being the research and development of oncology therapies. Its technologies are PTX-100, CellPryme, CellPryme-M, CellPryme-A, OmniCAR, etc.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 40.57 | |||||
Equity-to-Asset | 0.87 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.03 | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 20.6 | |||||
3-Year EPS without NRI Growth Rate | 11.2 | |||||
3-Year FCF Growth Rate | 8 | |||||
3-Year Book Growth Rate | -24.1 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 39.84 | |||||
9-Day RSI | 34.5 | |||||
14-Day RSI | 38.25 | |||||
3-1 Month Momentum % | 20.55 | |||||
6-1 Month Momentum % | 46.67 | |||||
12-1 Month Momentum % | 120 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 7.14 | |||||
Quick Ratio | 7.14 | |||||
Cash Ratio | 4.61 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -9.3 | |||||
Shareholder Yield % | -13.5 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -49.36 | |||||
ROA % | -42.59 | |||||
ROIC % | -180.34 | |||||
3-Year ROIIC % | -62.27 | |||||
ROC (Joel Greenblatt) % | -236.32 | |||||
ROCE % | -48.87 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 4.86 | |||||
Price-to-Tangible-Book | 6.8 | |||||
EV-to-EBIT | -8.96 | |||||
EV-to-EBITDA | -8.96 | |||||
EV-to-Forward-EBITDA | 1.58 | |||||
EV-to-Forward-Revenue | 18.37 | |||||
EV-to-FCF | -8.68 | |||||
| Price-to-Net-Current-Asset-Value | 6.8 | |||||
| Price-to-Net-Cash | 6.8 | |||||
Earnings Yield (Greenblatt) % | -11.16 | |||||
FCF Yield % | -10.1 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Prescient Therapeutics Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | |||
| EPS (TTM) (A$) | -0.007 | ||
| Beta | 0.5669 | ||
| 3-Year Sharpe Ratio | 0.18 | ||
| 3-Year Sortino Ratio | 0.32 | ||
| Volatility % | 96.04 | ||
| 14-Day RSI | 38.25 | ||
| 14-Day ATR (A$) | 0.003437 | ||
| 20-Day SMA (A$) | 0.0741 | ||
| 12-1 Month Momentum % | 120 | ||
| 52-Week Range (A$) | 0.04 - 0.125 | ||
| Shares Outstanding (Mil) | 1,051.51 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Prescient Therapeutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Prescient Therapeutics Ltd Stock Events
| Event | Date | Price (A$) | ||
|---|---|---|---|---|
| 0.05:1 Stock Split | 2014-12-02 | 0.13 (+0.00%) | ||
| 0.1:1 Stock Split | 2013-09-04 | 1.73 (+0.00%) | ||
| 1:1 Stock Split | 2009-11-25 | 9.63 (+0.00%) | ||
| 0.981547:1 Stock Split | 2006-09-27 | 30.04 (+0.00%) | ||
| 1.01729:1 Stock Split | 2005-11-29 | 28.63 (+3.23%) | ||
| 1.06247:1 Stock Split | 1997-07-17 | -- | ||
| 1:1 Stock Split | 1996-09-27 | -- | ||
| 1:1 Stock Split | 1995-06-27 | -- |
Show
Entries
Prescient Therapeutics Ltd Frequently Asked Questions
What is Prescient Therapeutics Ltd(ASX:PTX)'s stock price today?
The current price of ASX:PTX is A$0.07. The 52 week high of ASX:PTX is A$0.13 and 52 week low is A$0.04.
When is next earnings date of Prescient Therapeutics Ltd(ASX:PTX)?
The next earnings date of Prescient Therapeutics Ltd(ASX:PTX) is .
Does Prescient Therapeutics Ltd(ASX:PTX) pay dividends? If so, how much?
Prescient Therapeutics Ltd(ASX:PTX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Prescient Therapeutics Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers